“South Africa has begun the national rollout of Lenacapavir, a twice-yearly injectable HIV prevention treatment, hailed as one of the most significant advances in decades. The initiative aims to expand prevention choices, reduce stigma, and reach vulnerable populations, with the government targeting one million people by 2027.”
South Africa has taken a historic step in its battle against HIV/AIDS with the rollout of Lenacapavir, a revolutionary HIV prevention injection administered only twice a year. This development represents a paradigm shift in HIV prevention, moving away from daily oral regimens and toward long-acting, discreet, and highly effective solutions. With approximately 8 million South Africans living with HIV, the stakes could not be higher.
Background: HIV in South Africa
South Africa continues to carry one of the world’s heaviest HIV burdens. Data from 2025 revealed that 8.15 million people were living with HIV, accounting for nearly 13% of the population. Among adults aged 15–49, prevalence stood at 18.1%, with young women and adolescents disproportionately affected.
Despite progress in expanding access to antiretroviral therapy (ART), reducing new infections remains a critical challenge. Daily oral PrEP (pre-exposure prophylaxis) has been effective but faces barriers such as stigma, adherence difficulties, and accessibility issues.
Lenacapavir: A Game-Changer
Lenacapavir is a long-acting HIV prevention drug administered via injection every six months. Unlike oral PrEP, which requires daily intake, Lenacapavir offers continuous protection with just two doses per year. This innovation is expected to:
- Improve adherence by reducing the burden of daily medication.
- Reduce stigma, as the discreet injection avoids the visibility of pill-taking.
- Expand prevention choices, particularly for vulnerable groups such as adolescent girls, sex workers, and men who have sex with men.
Government Rollout Strategy
President Cyril Ramaphosa officially launched the rollout in Mpumalanga in June 2026, describing Lenacapavir as a “major breakthrough” in South Africa’s HIV response. The first phase targets 360 public clinics across six provinces, focusing on high-burden districts. The government’s immediate goal is to reach one million people by 2027, scaling up to three million within three years.
Public Health Impact
The rollout aligns with the Global AIDS Strategy 2026–2030, which emphasizes prevention as a cornerstone of epidemic control. By reducing new infections, Lenacapavir strengthens South Africa’s broader HIV response, complementing ART programs and supporting the goal of ending AIDS as a public health threat by 2030.
Experts believe Lenacapavir could significantly reduce infection rates among young women, who remain at the highest risk due to socio-economic vulnerabilities and gender inequalities.
Voices from Civil Society
The Treatment Action Campaign (TAC) welcomed the rollout, highlighting the drug’s potential to overcome stigma. Chairperson Sibongile Tshabalala noted that “with Lenacapavir, people can protect themselves discreetly, without the social judgment often associated with PrEP pills.”
Community organizations also emphasized the importance of accessibility, urging the government to ensure equitable distribution across rural and urban areas.
Challenges Ahead
While Lenacapavir represents a breakthrough, challenges remain:
- Cost and supply chain: Ensuring affordability and consistent availability of doses.
- Awareness campaigns: Educating communities about the benefits and safety of the injection.
- Equity in access: Preventing disparities between urban centers and rural communities.
Global Significance
South Africa’s rollout of Lenacapavir is being closely watched worldwide. As one of the countries hardest hit by HIV, its adoption of long-acting prevention could serve as a model for other nations. The initiative underscores Africa’s role in pioneering innovative public health solutions.
Conclusion
The rollout of Lenacapavir marks a turning point in South Africa’s fight against HIV/AIDS. By offering a discreet, long-acting, and highly effective prevention method, the country is poised to make significant strides toward epidemic control. If successful, this initiative could redefine HIV prevention globally and bring South Africa closer to its ambitious goal of ending AIDS as a public health threat by 2030.
